The state administration for intellectual property rights of the people's Republic of China has issued the first patent for a coronavirus vaccine developed in the country. This was reported on Monday by the Xinhua News Agency, citing a statement from the Ministry.
This is a recombinant vaccine based on the Ad 5-nov adenovirus vector, jointly developed by Casino Biologics and the Institute for bioengineering research at the PLA Academy of military medical Sciences. During tests on rodents, doctors found that the vaccine has good immunogenicity and can cause the necessary cellular and humoral immune responses in a short time. According to the Agency, it can be quickly produced on a large scale.
In March, this drug became the first approved candidate vaccine for clinical trials. On June 11, the second stage of its clinical trials was completed. On June 25, the Central Military Council of the PRC approved the use of this medical drug for the special needs of the army.